FTFemke M. van Den Tillaart

Femke M. van Den Tillaart

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Femke M. van Den Tillaart has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Suzanne Yzer

    Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands

    3 shared publications
  • Carel B. Hoyng

    From the Department of Ophthalmology (F.M.V.D.T., C.B.H., S.Y.), Radboud University Medical Center, Nijmegen, the Netherlands

    2 shared publications
  • Jennifer M. Chang-Wolf

    Department of Ophthalmology (J.M.C.W., R.M.H.D., R.O.S., C.J.F.B.), Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Ophthalmology (J.M.C.W., H.M.A.F., C.J.F.B., E.H.C.V.D.), Leiden University Medical Center, Leiden, the Netherlands

    2 shared publications
  • Reinier O. Schlingemann

    Department of Ophthalmology (J.M.C.W., R.M.H.D., R.O.S., C.J.F.B.), Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Ocular Angiogenesis Group (R.O.S.), Amsterdam University Medical Centers, Amsterdam, the Netherlands; Department of Ophthalmology (R.O.S.), University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland

    2 shared publications
  • A. Komrojan

    Department of Ophthalmology Radboud University Medical Center Nijmegen The Netherlands

    1 shared publication
  • C. B. Hoyng

    Department of Ophthalmology Radboud University Medical Center Nijmegen The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Long-Term Follow-Up of PLACE and SPECTRA Trials: Outcomes After Successful and Unsuccessful Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

    by Femke M. van Den Tillaart, Jennifer M. Chang-Wolf, Helena M.A. Feenstra, Thomas J. van Rijssen, Carel B. Hoyng, Roselie M.H. Diederen, Reinier O. Schlingemann, Camiel J.F. Boon, Suzanne Yzer, Elon H.C. van Dijk

  • Exploring retinal and choroidal characteristics on multimodal imaging in resolved central serous chorioretinopathy

    by Femke M. van Den Tillaart, Jennifer M. Chang-Wolf, Carel B. Hoyng, Roselie M. H. Diederen, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk, Suzanne Yzer

    Objective Comparing multimodal imaging characteristics in patients with central serous chorioretinopathy (CSC) with spontaneous subretinal fluid (SRF) resolution to SRF resolution after half-dose photodynamic therapy (HD-PDT). Methods Forty-six patients with CSC who had spontaneous SRF resolution were compared with 46 age- and gender-matched CSC patients with SRF resolution after HD-PDT. Patients in the HD-PDT group were selected from the randomized multicentre PLACE and SPECTRA trials. In the 2 groups, differences were evaluated on fluorescein angiography (FA), indocyanine green angiography (ICGA), and fundus autofluorescence (FAF). Subfoveal choroidal thickness (SFCT), central foveal thickness (CFT), external limiting membrane (ELM) and ellipsoid zone (EZ) continuity, and pigment epithelial detachments (PEDs) were analysed on optical coherence tomography (OCT). Results The median time between the last observed SRF on OCT and the resolution visit was 10.0 weeks in both groups. At the visit after SRF resolution, the area of hyperfluorescence on ICGA was larger (p = 0.001), the SFCT was thicker (p = 0.006), and EZ continuity was observed less frequently (p = 0.008) in the spontaneous SRF resolution group when compared with the HD-PDT group. No differences were observed in CFT, ELM continuity, number of PEDs, and the area of hyperfluorescence on FA. Conclusions CSC patients with spontaneous SRF resolution presumably show less favourable choroidal anatomical characteristics in the short term, compared to CSC patients with resolution after HD-PDT, as the area of ICGA hyperfluorescence was larger and the SFCT was thicker after spontaneous resolution. This observation might explain why recurrences in CSC are seen less frequently after HD-PDT.

  • Open Access

    Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy

    by F. M. van Den Tillaart, A. Komrojan, C. B. Hoyng, J. P. Martinez Ciriano, S. Yzer

    Purpose: To evaluate anatomical and functional outcomes after a second photodynamic therapy (PDT) in patients with central serous chorioretinopathy (CSC), who had a recurrence of subretinal fluid (SRF) after a previously successful PDT.Methods: In this multicentre retrospective cohort study, we included patients with CSC who underwent a second PDT because of a recurrence of SRF after an effective first PDT with complete SRF resolution. Diagnosis of CSC was based on multimodal imaging. We evaluated the complete resolution rate of SRF after a second PDT with reduced settings. Also, visual acuity (VA), subfoveal ellipsoid zone (EZ) and subfoveal external limiting membrane (ELM) integrity before and after the first and the second PDT were studied.Results: A total of 88 patients were studied, of whom 18% were female. The mean age was 51.3 ± 10.5 years at the second PDT. At the first follow‐up visit after the second PDT (median of 44 days [IQR 40–51] after PDT), a complete resolution of SRF occurred in 64% of eyes. The median VA was 0.15 LogMAR before the second PDT and improved to 0.05 LogMAR (p < 0.001) after PDT. The EZ was continuous in 3% of patients before the second PDT, and EZ continuity increased to 27% at the first follow‐up visit after PDT. No new atrophy was observed after the second PDT.Conclusion: A second PDT with reduced settings in recurrent CSC is effective and safe in the short term, as significant anatomical and functional improvement was observed.


  • Open Access

    PREDNISOLONE EYE DROPS AS A POTENTIAL TREATMENT IN NONNEOVASCULAR PACHYCHOROID-RELATED DISEASES

    by Femke M. van Den Tillaart, Irene M. Temmerman, Franca Hartgers, Suzanne Yzer

    Purpose: To investigate the functional and structural outcomes after treatment with prednisolone eye drops in the following pachychoroid-related diseases: chronic central serous chorioretinopathy, pachychoroid pigment epitheliopathy, and peripapillary pachychoroid syndrome. Methods: In this retrospective study, 54 eyes of 48 patients with pachychoroid-related disease were treated with prednisolone acetate 1% eye drops 3 times a day. Change in macular volume and retinal central subfield thickness on optical coherence tomography was measured. In addition, the foveal or complete resolution of fluid and the change in visual acuity were studied. Results: The follow-up visit was at a mean of 41.2 ± 14.5 days. In the 44 eyes with chronic central serous chorioretinopathy, a significant reduction in retinal central subfield thickness (P < 0.001) and macular volume (P < 0.001) was observed. Foveal intra- or subretinal fluid resolved completely in 22% of the eyes. In the 8 peripapillary pachychoroid syndrome eyes, a reduction in the nasal retinal thickness was observed (P = 0.025). One of the 2 pachychoroid pigment epitheliopathy eyes showed structural improvement. No significant change in visual acuity was observed in any of the pachychoroid spectrum diseases. Conclusion: In patients with chronic central serous chorioretinopathy, peripapillary pachychoroid syndrome, and pachychoroid pigment epitheliopathy, anatomical improvement was observed after therapy with prednisolone eye drops. Visual acuity did not change significantly.